Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Next Up For AstraZeneca: Building Out In Renal Disease

Oct 24 2018

• By Jessica Merrill

Ruud Dobber — AstraZeneca US President Ruud Dobber

Related Content

Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics

Oct 21 2018

Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

Jan 15 2018

AstraZeneca’s ZS-9 Delay In US Gives Veltassa An Edge

Mar 20 2017

AstraZeneca’s Lokelma Approved In US With Label Benefits Over Veltassa

May 21 2018

AstraZeneca's Oncology Business Delivers, Edging Toward CV/Metabolic As Top Contributor

Jul 26 2018

Related Companies

AstraZeneca PLC

ZS Pharma

CSL Vifor

FibroGen, Inc.

GSK plc

Viatris Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Leadership Launches Business Strategies Commercial Renal BioPharmaceutical

More from Leadership

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.